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ABSTRACT
The diagnostic work-up of acute promyelocytic leukemia (APL) includes the 
cytogenetic demonstration of the t(15;17) translocation and/or the PML-RARA 
chimeric transcript by RQ-PCR or RT-PCR. This latter assays provide suitable results in 
3-6 hours. We describe here two new, rapid and specific assays that detect PML-RARA 
transcripts, based on the RT-QLAMP (Reverse Transcription-Quenching Loop-mediated 
Isothermal Amplification) technology in which RNA retrotranscription and cDNA 
amplification are carried out in a single tube with one enzyme at one temperature, in 
fluorescence and real time format. A single tube triplex assay detects bcr1 and bcr3 
PML-RARA transcripts along with GUS housekeeping gene. A single tube duplex assay 
detects bcr2 and GUSB. In 73 APL cases, these assays detected in 16 minutes bcr1, 
bcr2 and bcr3 transcripts. All 81 non-APL samples were negative by RT-QLAMP for 
chimeric transcripts whereas GUSB was detectable. In 11 APL patients in which RT-
PCR yielded equivocal breakpoint type results, RT-QLAMP assays unequivocally and 
accurately defined the breakpoint type (as confirmed by sequencing). Furthermore, 
RT-QLAMP could amplify two bcr2 transcripts with particularly extended PML exon 6 
deletions not amplified by RQ-PCR. RT-QLAMP reproducible sensitivity is 10-3 for bcr1 
and bcr3 and 10-2 for bcr2 thus making this assay particularly attractive at diagnosis 
and leaving RQ-PCR for the molecular monitoring of minimal residual disease during 
the follow up. In conclusion, PML-RARA RT-QLAMP compared to RT-PCR or RQ-PCR is a 
valid improvement to perform rapid, simple and accurate molecular diagnosis of APL.
INTRODUCTION
Acute Promyelocytic Leukemia (APL) is a subtype 
of Acute Myeloid Leukemia (AML) characterized by 
a specific morphology of the tumor cells [1] and by a 
balanced reciprocal translocation t(15;17) which fuses 
the PML gene on chromosome 15 to the RARA gene 
on chromosome 17 [2-6]. The onset of the disease is 
also frequently characterized by a severe coagulopathy 
that exposes patients to high risk of fatal bleedings [7]. 
Interestingly, the incidence of APL and particularly its 
prevalence amongst AMLs seem to be different among 
ethnical groups and geographic areas and the disease 
has been reported as particularly frequent in developing 
countries of Latin America [8]. Beyond the evaluation 
of a blood and/or marrow smear, the diagnostic work-up 
of this leukemia includes conventional or fluorescent in 
situ hybridization (FISH) cytogenetic [9] and molecular 
detection of the PML-RARA fusion gene [10]. In 
addition, the diagnosis of APL may be obtained by 
immunofluorescence staining using a specific anti-PML 
antibody that recognizes a distinctive nuclear distribution 
pattern of the translocated PML protein [11, 12]. The 
latter does not, however, distinguish the variable PML-
RARA isoforms whose precise identification is essential 
for successive molecular monitoring of minimal residual 
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disease during follow-up [10, 13].
The accuracy and speed of the diagnostic work up 
is mandatory to start as soon as possible the life-saving 
treatment with all-trans retinoic acid (ATRA) combined 
with anthracycline or arsenic trioxide (ATO). These 
strategies have dramatically changed the natural history of 
this disease and converted APL from a highly fatal into a 
highly curable leukemia [14]. Unfortunately, a significant 
proportion of patients still do not benefit from these highly 
effective treatments due to an undue delay of diagnosis 
that may lead to life-threatening coagulopathy or because 
the onset itself of the disease is characterized by a fatal 
central nervous system (CNS) hemorrhage [15]. Based 
on current guidelines of the LeukemiaNet panel [16], 
immediate recommended actions should be based on the 
sole morphologic suspicion of APL and these include the 
start of ATRA and supportive care therapy and sending 
a blood marrow sample to a reference laboratory for 
molecular testing. Confirmation of diagnosis at the genetic 
level is considered essential for patient eligibility to ATRA 
and/or ATO-based treatments [16]. 
Identification of PML-RARA chimeric transcripts 
using Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) or Real-time Quantitative PCR (RQ-PCR) 
is performed in specialized laboratories that deliver the 
diagnosis in approximately 3-6 hours [13, 17, 18]. A 
simple and rapid molecular assay for APL may improve 
patient management and, as such, should ideally be 
feasible even in routine clinical laboratories outside 
specialized centers or in developing countries where 
significant improvements in the outcome of APL patients 
has been already achieved thanks to networking initiatives 
[19].
The loop-mediated isothermal amplification 
(LAMP) technology is an innovative non-PCR based 
nucleic acid amplification method that rapidly amplifies 
DNA or RNA targets under isothermal conditions 
[20]. LAMP is performed using strand-displacement 
polymerase and does not require Taq DNA polymerase 
or thermal cycling. The potential diagnostic applications 
of this technology are remarkable and rapidly expanding, 
particularly in the field of infectious [21] and hematologic 
diseases [22, 23]. With this background, we show that an 
improved version of LAMP technology allows a rapid, 
simple and accurate diagnosis of APL.
RESULTS
Development of a new quantitative, fluorescent 
LAMP assays (RT-QLAMP) for PML-RARA
The loop-mediated isothermal amplification 
(LAMP) technology is able to rapidly amplify DNA 
at constant temperature due to the utilization of a DNA 
polymerase with an additional strand displacement activity 
[20] (see Figure 1 and methods section). We modified this 
method by introducing fluorescent oligonucleotides and 
a new polymerase with both RNA retrotranscription and 
DNA amplification activity allowing single tube target 
amplification with one enzyme at one temperature, in a 
fluorescence and real time format (RT-QLAMP). We 
applied this new methodology to the identification of 
PML-RARA chimeric gene in APL. Two RT-QLAMP 
assays were designed to detect the 3 PML-RARA 
chimeric transcripts (bcr1, bcr2 and bcr3). One assay 
was developed for the simultaneous amplification in a 
single tube of bcr1 and bcr3, and GUSB housekeeping 
gene as an internal control (triplex assay) (Figure 2A). 
This assay may provide molecular diagnosis in 95% of 
APL cases. To set up this triplex RT-QLAMP assay we 
used NB4 cell line (bcr1 positive) and APL patients (bcr3 
positive) RNA. Representative fluorescence quenching 
curves for bcr1, bcr3 and GUSB are shown in Figure 
3A-B and C respectively. All 30 bcr1 and 30 bcr3 positive 
RNA samples tested were correctly amplified by the RT-
QLAMP triplex assay.
A separate assay was set up for the bcr2 and GUSB 
amplification (duplex assay) (Figure 2B). Representative 
fluorescence quenching curves are in Figure 3D-E for 
bcr2 and GUSB respectively. All 6 APL bcr2 samples (as 
assessed by RT-PCR) were correctly detected by the RT-
QLAMP duplex assay.
The average detection time for all APL patients 
of PML-RARA transcripts with RT-QLAMP assays was 
16±1 minutes while PML-RARA negativity (amplification 
of GUSB only) could be assessed in non APL samples in 
30 minutes (Figure 3A-E). Thus, PML-RARA RT-QLAMP 
assays provide molecular diagnosis of APL at least 4 hours 
before RT-PCR (Figure 4). 
RT-QLAMP assays were also tested on 699 
replicates of RNA from 8 cell lines negative for 
PML-RARA fusion gene showing a 100% specificity 
(confidence interval: 99.47-100). All replicates proved 
negative for PML-RARA and, as expected, positive for 
the internal control GUSB.
Validation of PML-RARA RT-QLAMP assays on 
clinical samples 
Seventy-three samples collected from two different 
sets of molecularly confirmed APL patients were selected 
and tested in blind by RT-QLAMP to confirm the diagnosis 
and the breakpoint type. Both PML-RARA RT-QLAMP 
assays correctly identified the 73 APL samples as well as 
81 APL-negative controls run in parallel (100% sensitivity 
and specificity). In 11 cases for whom the RT-PCR assay 
failed to clearly discriminate between bcr1 or bcr2 (the 
two chimeric transcripts may be different for only a small 
number of deleted nucleotides) the breakpoint type could 
be correctly defined by RT-QLAMP as bcr1 in nine cases 
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Table 1: Samples with ambiguous breakpoint definition by conventional RT-PCR tested by RT-QLAMP and confirmed 
by Sanger sequencing 
Sample RT-PCR result RT-Q-LAMP result Sequencing result
5322BG104 Equivocal bcr1/bcr2 bcr1 bcr1
15113BG105 Equivocal bcr1/bcr2 bcr1 bcr1
5734BG120 Equivocal bcr1/bcr2 bcr1 bcr1
2514BG126 bcr3 bcr1 bcr1
BM1547/12 Equivocal bcr1/bcr2 bcr1 bcr1
BM1666/12 Equivocal bcr1/bcr2 bcr1 bcr1
BM1685/12 Equivocal bcr1/bcr2 bcr1 bcr1
BM1722/12 Equivocal bcr1/bcr2 bcr1 bcr1
BM1724/12 Equivocal bcr1/bcr2 bcr1 bcr1
BM560/13 Equivocal bcr1/bcr2 bcr1 bcr1
BM512/12 Equivocal bcr1/bcr2 bcr2 bcr2
Figure 1: The LAMP technology principle. At a constant reaction temperature FIP and BIP primers are extended on the target DNA 
and the newly synthesized DNA chains are then displaced by extension of F3 and B3 (Panel A). The displaced product generates a “stem-
loop structure” which represents the starting structure for a LAMP reaction (Panel B).
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Figure 2: PML-RARA RQ-LAMP assays design. Panel A: schematic representation of the triplex assay which can amplify in a single 
tube bcr1, bcr3 and GUSβ. It provides the molecular diagnosis in 95% of APL cases. Oligonucleotide primers position for amplification are 
indicated. Panel B: schematic representation of the duplex assay for the amplification of bcr2 isoform, present in 5% of APL cases.
Figure 3: PML-RARA RQ-LAMP amplification plots. Representative amplification curves of bcr1 (Panel A), bcr3 (Panel B) and 
bcr2 (Panel D) PML-RARA positive cases obtained with triplex and duplex assays, respectively. Negative controls are represented in Panel 
C and E in which the only GUSβ gene is amplified.
Figure 4: Comparison between RT-PCR and RT-QLAMP workflow. RT-QLAMP assays provide results in 16±1 min for 
PML-RARA positive samples and in 30 minutes for negative samples. Conventional RT-PCR takes about 4.5 hours to have the analysis 
completed.
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and bcr2 in one as confirmed by direct sequencing (Table 
1). In addition, in one case (sample 2514BG126, Table 
1) RT-PCR incorrectly identified as bcr3 an unusual 
breakpoint (due to deletion of PML exon 5, Figure 5A-
B) which instead was accurately defined as bcr1 by RT-
QLAMP and DNA sequencing. Finally, two bcr2 cases 
which could not be amplified by RQ-PCR [13] because of 
particularly long deletions of PML exon 6 were properly 
amplified by RT-QLAMP (data not shown).
Detection limit of PML-RARA RT-QLAMP assays
The limits of detection sensitivity of the RT-QLAMP 
were evaluated on serial positive RNA dilutions (from 10-1 
to 10-5) in wild type HL-60 RNA. Sensitivity of bcr1 was 
10-3 in 98% of 367 replicates (Figure 6A and Table 2), 
10-3 for bcr3 (patient derived RNA, Figure 6B) and 10-2 in 
100% of replicates for bcr2. Using plasmids with cloned 
breakpoints, RT-QLAMP assays were able to detect up to 
20 DNA copies in 95% and 10 copies in 73% of replicates 
for bcr3 (Table 2) and 20 DNA copies in 99% of replicates 
for bcr2 (Figure 6C and Table 2). Interestingly, in all cases, 
the amplification of transcripts serially diluted in wild type 
RNA showed a quantitative pattern (Figure 6).
DISCUSSION
The novel RT-QLAMP assays here proposed to 
detect the PML-RARA chimeric transcripts allow target 
amplification in a single tube with one enzyme at one 
temperature, in a real time-fluorescence format and offers 
some advantages over conventional RT-PCR and RQ-PCR 
at diagnosis. Indeed, RT-QLAMP assays do not require a 
separate retro-transcription of RNA into cDNA before the 
Table 2: Performance of triplex and duplex assays in identifying PML-RARA variants when artificially diluted 
in HL60 RNA
Assay Variant Sample type Dilution Factor in HL60 % detection
R e p l i c a t e s 
Number
Triplex
Bcr1
NB4 RNA 10-3 97,8 367
NB4 RNA 10-4 36,7 30
Bcr1 patient RNA 10-3 100 4
Bcr3
Bcr3 containing plasmid 20 copies/reaction 95,2 290
Bcr3 containing plasmid 10 copies/reaction 73 37
Bcr3 patient RNA 10-3 100 4
Duplex Bcr2
Bcr2 containing plasmid 20 copies/reaction 99,6 229
Bcr2 patient RNA 10-2 100 2
Figure 5: PML-RARA variant with exon 5 deletion. 
Sanger sequencing of the peculiar PML-RARA variant (sample 
2514BG126, Table 1) with deletion of PML exon 5 (Panel A) 
and juxtaposition of PML exon 6 and RARA exon 3 of bcr1 
variant (Panel B). 
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amplification process since the DNA polymerase displays 
also reverse transcriptase activity, along with strand 
displacement activity that allows isothermal amplification. 
All in all, RT-QLAMP assays amplify chimeric PML-
RARA transcripts in approximately 15 minutes starting 
from RNA, providing molecular diagnosis of APL at least 
4 hours before RT-PCR and one hour before RQ-PCR. In 
addition, unlike conventional RT-PCR, the amplification 
products obtained by RT-QLAMP do not require any 
further manipulation since they are visualized as different 
fluorescent quenching signals specific for each of the three 
PML-RARA transcripts and for the internal control that 
allow real time monitoring and isoforms discrimination. 
The multiplex nature of RT-QLAMP has the 
additional distinguished feature of “true” internal control 
(GUSB) that is co-amplified with PML-RARA transcripts, 
allowing for accurate control of RNA extraction, RNA 
quality and amplification conditions, including incorrect 
assay set up or presence of inhibitors. The closed tube 
format from RNA to results also prevents DNA spillages 
and risk for cross-contamination.
Although no firm relationship between fusion 
variants and outcome has been reported [24] the correct 
definition of isoforms at diagnosis is essential for 
successive minimal residual disease monitoring by Real-
time Quantitative PCR (RQ-PCR) [16]. For this aspect, 
RT-QLAMP may offer some significant advantage 
compared to RT-PCR and RQ-PCR since it accurately 
defined the transcript type in 11 cases undefined by RT-
PCR, 1 case misclassified by RT-PCR and in 2 patients 
bearing a bcr2 rearrangement not amplified by the widely 
used EAC (Europe Against Cancer Program) RQ-PCR 
assay [13].
RT-QLAMP assay could be easily applied even in 
very small hospitals within non specialized laboratories 
thus avoiding any diagnostic delay related to the shipment 
of patients’ samples to reference hematological centers.
The LAMP technology was firstly developed as 
an isothermal reaction in which DNA amplification was 
detected by naked eye as precipitates formation during the 
reaction [21]. The RT-QLAMP for PML-RARA isoforms 
detection in the fluorescent, real time format described 
here or even the original, turbidity-based LAMP assay 
[22], could be also easily applied in developing countries 
to ensure rapid, simple and accurate diagnosis to all APL 
patients [25].
Although the RT-QLAMP can detect the presence 
of PML-RARA transcripts down to 10-3 (bcr1 and bcr3) 
or 10-2 (bcr2) positive RNA diluted in wild type RNA, this 
assay cannot be used in its present form as a quantitative 
assay for the detection of minimal residual disease during 
the follow-up. Therefore, at this time, the conventional 
nested PCR reaction or a RQ-PCR assay remain the 
reference methods for this purpose [26-28]. Nonetheless, 
the possibility to generate a quantitative Q-LAMP 
assay for detection of PML-RARA transcripts is under 
evaluation.
METHODS
Patients and samples
In this study we used total RNA derived from 93 
clinical samples (73 APL, 10 B cell Chronic Lymphocytic 
Leukemia (B-CLL), 4 B precursor Acute Lymphoid 
Leukemia, (ALL), 4 Acute Myeloid Leukemia (AML), 1 
Polycythemia Vera (PV), 1 Chronic Myeloid Leukemia 
(CML), and 61 healthy donors. These clinical samples 
were collected from 1995 to 2012 at two different clinical 
sites (Bergamo and Rome) from subjects who gave their 
informed consent. Total RNA was extracted by phenol-
chloroform extraction [29] or RNeasy mini kit (Qiagen, 
Hilden, Germany) from mononuclear cells isolated by 
Ficoll-Hypaque gradient centrifugation and lysed in 
guanidinium iso-thiocyanate (GITC). Samples were tested 
in blind.
Figure 6: PML-RARA RQ-LAMP limit of detection. RT-QLAMP amplification curves of bcr1, bcr3 and bcr2 variants from NB4 
cell line RNA (Panel A) or Patient RNA (Panel B and C, respectively) undiluted and serially diluted in HL60 RNA. Bcr1 and bcr3 limit of 
detection sensitivity is 10-3, while bcr2 sensitivity is 10-2. Interestingly dilutions of target are detected in a quantitative fashion.
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Cell Lines
The following human cell lines were used: NB4 
[t(15;17) APL], HL60 (AML, bearing the BCOR mutation) 
[30], KASUMI-1 [t(8;21) RUNX1- RUNX1T1 AML], 
K562 [t(9;22) BCR-ABL1 p210-positive chronic myeloid 
leukemia in erythroid blast crisis], TOM-1 [t(9;22) BCR-
ABL1, p190-positive ALL], 697 [t(1;19) TCF3-PBX1, 
ALL], RS411 and MV4 [both t(4;11) KMT2A-AFF1, 
positive ALLs], REH [t(12;21) ETV6-RUNX1, ALL] [10].
Conventional identification of PML-RARA 
chimeric transcripts
Identification of PML-RARA chimeric transcript 
was routinely performed on diagnostic total RNA by 
Reverse Transcriptase- Polymerase Chain Reaction (RT-
PCR). The PML-RARA different transcripts were searched 
in two separate PCR reactions, one for bcr1 and bcr2 
transcript variants and one for bcr3 variant as previously 
described [10, 18]. Samples positivity for PML-RARA 
transcripts was assessed by agarose gel electrophoresis 
of the amplification products. Amplification bands 
were detected by intercalating dye molecules and UV 
excitation. The RNA integrity and the efficiency of the 
retro-transcription step were evaluated for each cDNA by 
the amplification of the wild type ABL1 gene in a separate 
PCR reaction. RQ-PCR was performed according to EAC 
(Europe Against Cancer program) protocol [13].
RT-QLAMP
The loop-mediated isothermal amplification 
(LAMP) was initially described by Notomi to amplify 
DNA under isothermal conditions [20]. The LAMP 
reaction (Figure 1) is a non-PCR isothermal method for 
rapid amplification of nucleic acids. It is based on the 
use of four primers specifically designed to recognize six 
distinct regions on the target genes: a pair of outer primers 
(F3 and B3) and a pair of inner primers (FIP and BIP) 
presenting a tag complementary to a downstream region in 
the opposite strand of the target (F1 and B1). Each primer 
is 16-42 bp long. F3 and FIP primers are complementary 
to the PML region upstream the break point, whereas 
BIP and B3 primers to the RARA region downstream 
the break point. The reaction is conducted at a constant 
temperature in the presence of a DNA polymerase with 
strand displacement activity. The FIP and BIP primers 
anneal and are extended on the target DNA and the newly 
synthesized DNA chains are then displaced by extension 
of F3 and B3. The displaced product generates a “stem 
loop structure” which represents the starting structure for 
a classical LAMP reaction. By addition of labeled probes 
it is possible to monitor in real time the amplification onto 
the Liaison IAM instrument (DiaSorin, SpA). At time 
zero the reaction, excited with appropriate wavelength 
UV light, emits a maximum fluorescence. As a function 
of amplification, the fluorescence deceases exponentially 
thanks to the natural quenching effect of newly synthetized 
amplicons. The threshold minute is the minute at which 
the sample fluorescence reaches the 50% of quenching 
and is correlated with the amount of target present in 
the reaction. The RT-QLAMP (Reverse Transcriptase-
Quantitative LAMP) represents a further improvement of 
LAMP, allowing amplification of target starting directly 
from RNA thanks to the additional reverse transcriptase 
activity embedded in the DNA polymerase enzyme. The 
PML-RARA RT-QLAMP consists of two fluorescent 
multiplex assays, one specific for the most frequent 
transcripts (bcr1 and bcr3) and one for the rarer bcr2 
(information available upon request). Retrotranscription 
and amplification precede both at one constant temperature 
in a closed-tube format. To control extraction procedure, 
RNA integrity, reaction functionality and absence of 
inhibitors, both assays also detect the endogenous GUSβ 
housekeeping RNA as internal control. The amplification 
curves become visible in about 15 minutes for PML-
RARA positive samples. The implementation of 3 probes 
specific for the bcr1, bcr2, bcr3 transcripts, labeled 
with 3 different fluorochromes characterized by distinct 
wavelengths of emission, allows not only to detect the 
PML-RARA translocation, but also to distinguish the 
precise isoform. 
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